What Percentage of People Lose Weight on Wegovy?

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active ingredient in Wegovy, helped approximately 86% of people lose at least 5% of their body weight in clinical trials. However, success rates depend on individual biology, lifestyle, and medication adherence. PlexusDx provides compounded semaglutide therapy from licensed 503A pharmacies, making this proven weight-loss approach accessible across all 50 states without insurance.

Clinical Weight Loss Success Rates for Semaglutide

The STEP trials, which tested semaglutide at doses up to 2.4 mg weekly, demonstrated that 86% of participants achieved at least 5% weight loss—a medically meaningful threshold. More impressive, 69% lost at least 10% of their body weight, and 50% lost at least 15%. These results represent what happens when medication is combined with lifestyle counseling, making them realistic benchmarks for real-world use.

Weight loss typically appears gradual during the first 4–8 weeks as your body adapts to the medication. Most significant losses occur between months 3 and 6, with continued progress through month 12. Some people experience a plateau after month 6, which is normal; adjusting dose or lifestyle factors often helps restart progress.

Why Individual Results Vary on GLP-1 Therapy

Not everyone loses the same amount of weight on semaglutide because metabolism, appetite pathways, and medication response are shaped by genetics. Your GLP-1 receptor sensitivity, GIPR function, and genes affecting hunger hormones all influence how well a GLP-1 medication works for you. This is why some people see rapid, dramatic results while others experience steady, moderate loss.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Semaglutide Works to Support Weight Loss

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a natural hormone controlling blood sugar and appetite. When you take semaglutide, it slows stomach emptying, increases fullness signals to your brain, and reduces cravings—allowing you to eat less without feeling deprived. The medication also improves blood sugar control, which stabilizes energy and reduces hunger spikes.

These effects accumulate over weeks. Early on, you may notice smaller portions feeling satisfying. By week 4–6, intense food cravings often fade, and by month 3, most people report a fundamentally different relationship with food. This neurochemical shift, not willpower alone, is what drives the 86% success rate.

Compounded Semaglutide vs. Brand-Name Wegovy at PlexusDx

PlexusDx's compounded semaglutide injection contains the same active ingredient as Wegovy but costs significantly less: starting at $149 per month versus $900–$1,350 for brand-name Wegovy. Both are injected once weekly, both use identical dosing schedules, and both require monitoring. The difference is access: PlexusDx compounds semaglutide through licensed 503A pharmacies and serves all 50 states without requiring insurance or membership fees.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How to Maximize Your Weight Loss on Semaglutide

The 86% success rate assumes people follow their treatment plan consistently. Missing doses or injecting irregularly undermines results. Setting a weekly reminder and planning your injection day helps establish routine. Also, eating protein-rich foods, staying hydrated, and moving your body most days amplify semaglutide's effects—the medication works best alongside these habits, not instead of them.

Monitor how you feel during dose escalation phases. Some people experience nausea or constipation early; these side effects often improve as your body adjusts or when your care provider tweaks the dose schedule. Tracking your weight weekly and noting energy levels helps you and your provider assess whether you're on the right dose for your body.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What percentage of people actually lose weight on semaglutide?

In STEP clinical trials, 86% of participants lost at least 5% of their body weight on semaglutide 2.4 mg weekly. Approximately 69% achieved 10% weight loss, and 50% lost 15% or more. Real-world results vary based on genetics, adherence, and lifestyle factors.

How much weight can I expect to lose on Wegovy or semaglutide?

Average weight loss in trials was 15 pounds at 3 months, 30 pounds at 6 months, and 35–45 pounds by 12 months for people at higher doses. However, individual results range from 5% loss (medical success) to 20% or more. Genetics and behavior determine where you'll fall within that range.

Is compounded semaglutide from PlexusDx as effective as Wegovy?

Yes—compounded semaglutide contains the identical active pharmaceutical ingredient and uses the same injection schedule as Wegovy. PlexusDx sources from licensed 503A compounding pharmacies and costs significantly less ($189/month vs. $900+), making it accessible across all 50 states without insurance.

How long does it take to see weight loss results on semaglutide?

Most people notice appetite suppression within 1–2 weeks, but measurable weight loss typically appears after 4–8 weeks. The most significant drops occur between months 3 and 6. Continued progress is common through month 12 if you maintain the medication and healthy habits.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

PlexusDx's Precision Peptide Genetic Test analyzes variants in GIPR, FTO, and MC4R, and 10 other pathways controlling appetite and metabolism. While genetics don't guarantee results, they reveal your receptor sensitivity and predicted response to GLP-1 therapy, helping your provider optimize your treatment choice and dose starting at $298.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.